Alzheimer's disease Other Imaging Findings: Difference between revisions
Jump to navigation
Jump to search
Akshun Kalia (talk | contribs) No edit summary |
Akshun Kalia (talk | contribs) No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 2: | Line 2: | ||
{{Alzheimer's disease}} | {{Alzheimer's disease}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}}{{Akshun}} | ||
==Overview== | ==Overview== | ||
Other imaging studies in Alzheimer's include positron emission tomography (PET) and single photon emission computed tomography (SPECT) scan. PET and SPECT scan are not routinely done in Alzheimer's disease. However, patients with atypical presentation may be evaluated with either a PET or SPECT scan to assess for any underlying condition. In these patients, use of amyloid β PET scan will reveal lower FDG (fluorine-18 fluorodeoxyglucose) metabolism and higher PiB ([11 C]Pittsburgh compound B) deposition in areas of the brain affected by Alzheimer's disease. On SPECT scan patients with Alzheimer's disease have low relative regional cerebral blood flow (rCBF) in the parietal and prefrontal cortices. | Other [[imaging]] studies in Alzheimer's include [[positron emission tomography]] ([[PET]]) and [[single photon emission computed tomography]] ([[SPECT]]) scan. [[PET scan|PET]] and [[SPECT]] scan are not routinely done in Alzheimer's disease. However, [[patients]] with atypical presentation may be evaluated with either a [[PET scan|PET]] or [[SPECT]] scan to assess for any underlying condition. In these patients, use of [[Amyloid beta|amyloid β]] [[PET scan|PET]] scan will reveal lower [[FDG]] (fluorine-18 fluorodeoxyglucose) metabolism and higher PiB ([11 C]Pittsburgh compound B) deposition in areas of the [[brain]] affected by Alzheimer's disease. On [[SPECT]] scan patients with Alzheimer's disease have low relative regional [[cerebral blood flow]] (rCBF) in the [[parietal]] and [[Prefrontal cortex|prefrontal]] cortices. | ||
==Other Imaging Findings== | ==Other Imaging Findings== | ||
* Other imaging studies in Alzheimer's include positron emission tomography (PET) and single photon emission computed tomography (SPECT) scan. | Other imaging studies include:<ref name="Geda2012">{{cite journal|last1=Geda|first1=Yonas E.|title=Mild Cognitive Impairment in Older Adults|journal=Current Psychiatry Reports|volume=14|issue=4|year=2012|pages=320–327|issn=1523-3812|doi=10.1007/s11920-012-0291-x}}</ref><ref name="pmid15896221">{{cite journal |vauthors=Trollor JN, Sachdev PS, Haindl W, Brodaty H, Wen W, Walker BM |title=Regional cerebral blood flow deficits in mild Alzheimer's disease using high resolution single photon emission computerized tomography |journal=Psychiatry Clin. Neurosci. |volume=59 |issue=3 |pages=280–90 |year=2005 |pmid=15896221 |doi=10.1111/j.1440-1819.2005.01372.x |url=}}</ref><ref name="pmid16479105">{{cite journal |vauthors=Trollor JN, Sachdev PS, Haindl W, Brodaty H, Wen W, Walker BM |title=A high-resolution single photon emission computed tomography study of verbal recognition memory in Alzheimer's disease |journal=Dement Geriatr Cogn Disord |volume=21 |issue=4 |pages=267–74 |year=2006 |pmid=16479105 |doi=10.1159/000091433 |url=}}</ref><ref name="pmid24279935">{{cite journal |vauthors=Ferris SH, de Leon MJ, Wolf AP, Farkas T, Christman DR, Reisberg B, Fowler JS, Macgregor R, Goldman A, George AE, Rampal S |title=Positron emission tomography in the study of aging and senile dementia |journal=Neurobiol. Aging |volume=1 |issue=2 |pages=127–31 |year=1980 |pmid=24279935 |doi= |url=}}</ref><ref name="pmid3488245">{{cite journal |vauthors=Rapoport SI |title=Positron emission tomography in normal aging and Alzheimer's disease |journal=Gerontology |volume=32 Suppl 1 |issue= |pages=6–13 |year=1986 |pmid=3488245 |doi= |url=}}</ref><ref name="pmid2948218">{{cite journal |vauthors=Cutler NR |title=Cerebral metabolism as measured with positron emission tomography (PET) and [18F] 2-deoxy-D-glucose: healthy aging, Alzheimer's disease and Down syndrome |journal=Prog. Neuropsychopharmacol. Biol. Psychiatry |volume=10 |issue=3-5 |pages=309–21 |year=1986 |pmid=2948218 |doi= |url=}}</ref> | ||
* PET and SPECT scan are not routinely done in Alzheimer's disease. However, patients with atypical presentation may be evaluated with either a PET or SPECT scan to further assess the patient for any underlying condition. | |||
* The Amyloid Imaging Taskforce (AIT) recommends use of amyloid β (Aβ) positron emission tomography (PET) scanning in atypical cases of Alzheimer's. | * Other [[imaging]] studies in Alzheimer's include [[positron emission tomography]] ([[PET scan|PET]]) and [[single photon emission computed tomography]] ([[SPECT]]) scan. | ||
* The tracer used in PET scan for amyloid β include [11 C]Pittsburgh compound B (PiB) and fluorine-18 fluorodeoxyglucose(FDG). | * [[PET scan|PET]] and [[SPECT]] scan are not routinely done in Alzheimer's disease. However, patients with atypical presentation may be evaluated with either a [[PET scan|PET]] or [[SPECT]] scan to further assess the patient for any underlying condition. | ||
* Patients with atypical presentation of Alzheimer's and a greater decline in memory function will have lower FDG metabolism and higher PiB deposition in areas of the brain affected by Alzheimer's disease. | * The Amyloid Imaging Taskforce (AIT) recommends use of [[Amyloid beta|amyloid β]] ([[Aβ]]) [[positron emission tomography]] ([[PET]]) scanning in atypical cases of Alzheimer's. | ||
* According to the guidelines of AIT, amyloid β PET scan is recommended in cases of: | * The [[tracer]] used in [[PET scan|PET]] scan for [[Amyloid beta|amyloid β]] include [11 C]Pittsburgh compound B (PiB) and fluorine-18 fluorodeoxyglucose([[FDG]]). | ||
** Patients with persistent or progressive unexplained mild cognitive impairment | * Patients with atypical presentation of Alzheimer's and a greater decline in [[memory]] function will have lower [[FDG]] metabolism and higher PiB deposition in areas of the brain affected by Alzheimer's disease. | ||
* According to the guidelines of AIT, [[Amyloid beta|amyloid β]] [[PET scan|PET]] scan is recommended in cases of: | |||
** Patients with persistent or progressive unexplained [[mild cognitive impairment]] | |||
** Patients with early age onset | ** Patients with early age onset | ||
** Patients with progressive dementia | ** Patients with progressive [[dementia]] | ||
* In SPECT scan, patients are given a simple word-discrimination task and then observed for gradation of cerebral blood flow (rCBF). | * In [[SPECT]] scan, patients are given a simple word-discrimination task and then observed for gradation of regional [[cerebral blood flow]] (rCBF). | ||
* Patients with Alzheimer disease have low relative regional cerebral blood flow (rCBF) in the parietal and prefrontal cortices. | * Patients with Alzheimer disease have low relative regional [[cerebral blood flow]] (rCBF) in the [[parietal]] and [[Prefrontal cortex|prefrontal]] cortices. | ||
==References== | ==References== | ||
Latest revision as of 14:27, 21 September 2017
|
Alzheimer's disease Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Alzheimer's disease Other Imaging Findings On the Web |
|
American Roentgen Ray Society Images of Alzheimer's disease Other Imaging Findings |
|
Risk calculators and risk factors for Alzheimer's disease Other Imaging Findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]
Overview
Other imaging studies in Alzheimer's include positron emission tomography (PET) and single photon emission computed tomography (SPECT) scan. PET and SPECT scan are not routinely done in Alzheimer's disease. However, patients with atypical presentation may be evaluated with either a PET or SPECT scan to assess for any underlying condition. In these patients, use of amyloid β PET scan will reveal lower FDG (fluorine-18 fluorodeoxyglucose) metabolism and higher PiB ([11 C]Pittsburgh compound B) deposition in areas of the brain affected by Alzheimer's disease. On SPECT scan patients with Alzheimer's disease have low relative regional cerebral blood flow (rCBF) in the parietal and prefrontal cortices.
Other Imaging Findings
Other imaging studies include:[1][2][3][4][5][6]
- Other imaging studies in Alzheimer's include positron emission tomography (PET) and single photon emission computed tomography (SPECT) scan.
- PET and SPECT scan are not routinely done in Alzheimer's disease. However, patients with atypical presentation may be evaluated with either a PET or SPECT scan to further assess the patient for any underlying condition.
- The Amyloid Imaging Taskforce (AIT) recommends use of amyloid β (Aβ) positron emission tomography (PET) scanning in atypical cases of Alzheimer's.
- The tracer used in PET scan for amyloid β include [11 C]Pittsburgh compound B (PiB) and fluorine-18 fluorodeoxyglucose(FDG).
- Patients with atypical presentation of Alzheimer's and a greater decline in memory function will have lower FDG metabolism and higher PiB deposition in areas of the brain affected by Alzheimer's disease.
- According to the guidelines of AIT, amyloid β PET scan is recommended in cases of:
- Patients with persistent or progressive unexplained mild cognitive impairment
- Patients with early age onset
- Patients with progressive dementia
- In SPECT scan, patients are given a simple word-discrimination task and then observed for gradation of regional cerebral blood flow (rCBF).
- Patients with Alzheimer disease have low relative regional cerebral blood flow (rCBF) in the parietal and prefrontal cortices.
References
- ↑ Geda, Yonas E. (2012). "Mild Cognitive Impairment in Older Adults". Current Psychiatry Reports. 14 (4): 320–327. doi:10.1007/s11920-012-0291-x. ISSN 1523-3812.
- ↑ Trollor JN, Sachdev PS, Haindl W, Brodaty H, Wen W, Walker BM (2005). "Regional cerebral blood flow deficits in mild Alzheimer's disease using high resolution single photon emission computerized tomography". Psychiatry Clin. Neurosci. 59 (3): 280–90. doi:10.1111/j.1440-1819.2005.01372.x. PMID 15896221.
- ↑ Trollor JN, Sachdev PS, Haindl W, Brodaty H, Wen W, Walker BM (2006). "A high-resolution single photon emission computed tomography study of verbal recognition memory in Alzheimer's disease". Dement Geriatr Cogn Disord. 21 (4): 267–74. doi:10.1159/000091433. PMID 16479105.
- ↑ Ferris SH, de Leon MJ, Wolf AP, Farkas T, Christman DR, Reisberg B, Fowler JS, Macgregor R, Goldman A, George AE, Rampal S (1980). "Positron emission tomography in the study of aging and senile dementia". Neurobiol. Aging. 1 (2): 127–31. PMID 24279935.
- ↑ Rapoport SI (1986). "Positron emission tomography in normal aging and Alzheimer's disease". Gerontology. 32 Suppl 1: 6–13. PMID 3488245.
- ↑ Cutler NR (1986). "Cerebral metabolism as measured with positron emission tomography (PET) and [18F] 2-deoxy-D-glucose: healthy aging, Alzheimer's disease and Down syndrome". Prog. Neuropsychopharmacol. Biol. Psychiatry. 10 (3–5): 309–21. PMID 2948218.